Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021
In this cohort of patients with cSLE who received inpatient treatment with rituximab, we observed a 14% rate of hospitalisation with infection in the year following rituximab administration among youth with cSLE. Rituximab use declined during the COVID-19 pandemic. No fatalities with COVID-19 were observed. Given the lack of outpatient data, including doses of concomitant medications and disease activity measures, further research is needed to identify risk factors for infection following rituximab among children with cSLE.
Authors
- Jonathan D. Cogen (ORCID: https://orcid.org/0000-0002-0382-6858)
- Anna Faino (ORCID: https://orcid.org/0000-0001-9427-9548)
- Jordan E. Roberts (ORCID: https://orcid.org/0000-0002-0976-5697)
- Mersine A. Bryan
- Esi M. Morgan (ORCID: https://orcid.org/0000-0002-8235-1781)
Institutions
- Seattle Children's Hospital (US)
- University of Washington (US)
- Cancer Research And Biostatistics (US)
- Seattle Children's Hospital (US)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/lupus-2024-001210
- Citations
- 3
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Arthritis Foundation
- Lupus Foundation of America
- Seattle Children's Research Institute
- Children’s Hospital of Wisconsin Research Institute
- Childhood Arthritis and Rheumatology Research Alliance
- Center for Clinical and Translational Research